Value of pyrazinamide for composition of new treatment regimens for multidrug-resistant Mycobacterium tuberculosis in China.
Hui XiaSusan van den HofFrank CobelensYang ZhouBing ZhaoShengfen WangYan-Lin ZhaoPublished in: BMC infectious diseases (2020)
Pyrazinamide resistance among MDR-TB patients in China is common, although less so in elderly patients. Therefore, pyrazinamide should only be used for treatment of RR/MDR-TB in China if susceptibility is confirmed. Molecular testing for detection of pyrazinamide resistance only based on pncA mutations has certain value for the rapid detection of pyrazinamide resistance in MDR-TB strains but other gene mutations conferring to pyrazinamide resistance still need to be explored to increase its predictive ability .
Keyphrases
- mycobacterium tuberculosis
- multidrug resistant
- pulmonary tuberculosis
- drug resistant
- end stage renal disease
- gram negative
- acinetobacter baumannii
- ejection fraction
- klebsiella pneumoniae
- chronic kidney disease
- newly diagnosed
- prognostic factors
- combination therapy
- peritoneal dialysis
- single molecule
- replacement therapy
- pseudomonas aeruginosa